1.Premature ovarian insufficiency: When ovaries retire early.
Stella Rizalina Sasha SUGIANTO ; Lisa WEBBER ; Farah SAFDAR HUSAIN ; Veronique VIARDOT-FOUCAULT ; Sadhana NADARAJAH ; Jiin Ying LIM ; Ee Shien TAN ; Tze Tein YONG ; Rukshini PUVANENDRAN
Annals of the Academy of Medicine, Singapore 2025;54(3):178-191
INTRODUCTION:
Premature ovarian insufficiency (POI) refers to loss of ovarian activity before the age 40 years. POI has significant detrimental effects on health (infertility, cardiovascular diseases, type 2 diabetes, reduced bone density, dementia), well-being and longevity. This summary is a practical toolkit for health-care professionals (HCPs) looking after women with POI.
METHOD:
A workgroup comprising specialists in gynaecology, reproductive medicine, endocrinology, genetics and family medicine reviewed relevant guidelines and literature on POI to establish recom-mendations for the diagnosis and management of POI in Singapore.
RESULTS:
A summary to assist HCPs manage POI was produced, outlining: (1) the aetiology and conse-quences of POI; (2) making the diagnosis; (3) hormone therapy (HT) prescribing options including for those with additional medical conditions; (4) counselling women with POI about HT; and (5) long-term management of POI.
CONCLUSION
Timely diagnosis and management of POI is vital to prevent long-term adverse consequences, except infertility. HT is the mainstay of treatment and there are no alternatives as effective. Contraindications are very few; estrogen-sensitive cancer is the main contraindication, and caution in prescribing may be needed with established coexisting cardiovascular disease. Estrogen dosage is higher than when treating normal menopause, and as a result, the patient might require more progestogen for endometrial protection. Minimising cardiovascular risk factors by following a healthy lifestyle is important. POI is a significant public health issue and it is imperative that women have affordable access to appropriate HT. Large-scale research on POI in Asian women is needed.
Humans
;
Primary Ovarian Insufficiency/drug therapy*
;
Female
;
Estrogen Replacement Therapy
;
Singapore
;
Adult

Result Analysis
Print
Save
E-mail